Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gyre Therapeutics ( (GYRE) ) has issued an update.
On March 2, 2026, Gyre Therapeutics agreed to acquire privately held Cullgen Inc. in an all-stock deal valuing Cullgen at roughly $300 million, with Cullgen to become a wholly owned subsidiary and the merger structured as a tax-free reorganization. The combination will add Cullgen’s targeted protein degrader and degrader-antibody conjugate platforms and clinical pipeline in pain, cancer and inflammatory diseases to Gyre’s commercial fibrosis franchise and China-based manufacturing and sales infrastructure.
Under the merger terms, Cullgen shareholders will receive Gyre common or Series B convertible preferred stock, while in-the-money Cullgen options roll into Gyre options and restricted stock units vest into Gyre shares, subject to a 19.99% cap on Gyre common stock issuance before conversion approval. The deal will also reshape leadership, with Cullgen CEO Ying Luo set to become Gyre’s chief executive and president while two Gyre directors, including its president, resign and the board shrinks to seven members.
To facilitate the transaction structure, Gyre plans to file a new Certificate of Designation creating Series B preferred shares that carry common-stock-equivalent dividends, limited voting rights and the ability to convert into common stock at a 5:1 ratio after stockholder approval, subject to individual ownership caps below 19.99%. The acquisition, expected to close early in the second quarter of 2026 pending customary U.S. regulatory approvals, is positioned to create a fully integrated biopharmaceutical company with revenue-generating assets and a diversified pipeline spanning fibrosis, oncology, inflammatory diseases and pain.
The most recent analyst rating on (GYRE) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
The score is primarily driven by mixed financial performance—strong margins and a low-leverage balance sheet but material cash flow weakness. Technicals are bearish with price below key moving averages and negative MACD, and valuation is stretched due to a very high P/E. These are partially offset by a positive corporate catalyst from progress toward potential China approval for Hydronidone.
To see Spark’s full report on GYRE stock, click here.
More about Gyre Therapeutics
Gyre Therapeutics is a San Diego-based biopharmaceutical company focused on developing and commercializing therapies for organ fibrosis, notably Hydronidone for liver fibrosis including MASH in the U.S. Through its 69.7% stake in China-based Gyre Pharmaceuticals, it markets ETUARY for idiopathic pulmonary fibrosis and advances a broad fibrosis and respiratory pipeline.
Gyre Pharmaceuticals generated $105.8 million in ETUARY net sales in 2024 in China and is progressing Hydronidone toward an NDA for CHB-associated liver fibrosis, alongside programs for pulmonary and acute liver conditions. The group aims to leverage integrated research, development, manufacturing and commercialization capabilities across the U.S. and China.
Average Trading Volume: 80,342
Technical Sentiment Signal: Hold
Current Market Cap: $748.9M
See more data about GYRE stock on TipRanks’ Stock Analysis page.